Evercore ISI Begins Coverage on Regeneron Pharmaceuticals (NASDAQ:REGN)

Evercore ISI assumed coverage on shares of Regeneron Pharmaceuticals (NASDAQ:REGNFree Report) in a research report sent to investors on Tuesday morning, Benzinga reports. The firm issued an outperform rating and a $1,150.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts also recently weighed in on the company. TD Cowen upped their price target on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a buy rating in a research report on Wednesday, April 24th. Sanford C. Bernstein began coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an outperform rating and a $1,125.00 target price for the company. Royal Bank of Canada reissued an outperform rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a research report on Tuesday, April 9th. BMO Capital Markets raised their price objective on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the company an outperform rating in a report on Monday, February 5th. Finally, Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an overweight rating in a research report on Wednesday, March 13th. One research analyst has rated the stock with a sell rating, four have given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of Moderate Buy and a consensus target price of $989.36.

Get Our Latest Analysis on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Up 1.5 %

REGN stock opened at $982.29 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The stock has a market capitalization of $108.23 billion, a P/E ratio of 29.02, a P/E/G ratio of 1.99 and a beta of 0.17. Regeneron Pharmaceuticals has a fifty-two week low of $684.80 and a fifty-two week high of $998.33. The business has a 50-day moving average of $942.68 and a 200-day moving average of $908.10.

Insiders Place Their Bets

In other news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the transaction, the director now owns 18,282 shares of the company’s stock, valued at $17,953,838.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $982.05, for a total value of $98,205.00. Following the completion of the sale, the director now directly owns 18,282 shares in the company, valued at approximately $17,953,838.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Joseph J. Larosa sold 1,000 shares of the company’s stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $967.65, for a total value of $967,650.00. Following the completion of the transaction, the executive vice president now directly owns 37,543 shares in the company, valued at $36,328,483.95. The disclosure for this sale can be found here. Insiders sold 55,925 shares of company stock worth $54,616,836 over the last three months. Insiders own 8.83% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of REGN. West Paces Advisors Inc. raised its position in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares in the last quarter. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $28,000. Annis Gardner Whiting Capital Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter valued at $26,000. Fortitude Family Office LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter worth $31,000. Finally, MCF Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Recommended Stories

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.